NCT03361735View on ClinicalTrials.gov

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

February 4, 2026

Study Completion Date

February 4, 2026

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Leuprolide Acetate

Intramuscular or subcutaneous injection

DRUG

Goserelin Acetate

Subcutaneous injection

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

RADIATION

Radium Ra 223 Dichloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Degarelix

Subcutaneous injection

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER

NCT03361735 - Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter